Approval Alert | Amivantamab/Chemo in EGFR Exon 20+ NSCLC

Data from the phase 3 PAPILLON trial support the FDA approval of amivantamab plus chemotherapy for patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.